Drug Trial Radar · NCT06148792
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
Last checked: Nov 19, 2026Latest source record: Jul 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,090
Planned (sponsor's estimate)
Start
May 10, 2024
Primary completion
Mar 1, 2027
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- Menzies School of Health ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Melbourne; Fundação de Medicina Tropical Dr. Heitor Vieira Dourado; Arba Minch University; Addis Ababa University; Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Indonesia; Curtin University; Papua New Guinea Institute of Medical Research
- First posted
- Nov 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the efficacy and safety or a revised weight band tafenoquine dose in vivax malaria patients. The main question\[s\] it aims to answer are: * is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) non-inferior to high dose primaquine (7mg/kg over 7 days) * is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) superior to fixed dose tafenoquine (300mg) * is the tolerability and safety of TQRevised acceptable * is TQRevised acceptable and feasible Participants will receive a tafenoquine target dose 7.5mg/kg in weight bands. Researchers will compare this to patients receiving a fixed dose tafenoquine and high dose primaquine to see if safe and effective.
Conditions
- Vivax Malaria
Interventions
TafenoquineDrug
oral treatment
PrimaquineDrug
oral treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence risk of vivax parasitaemiaTime frame: 4 months
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Dr Marcus Lacerda
Manaus, Brazil · Recruiting
Arba Minch General Hospital
Arba Minch, Ethiopia · Recruiting
Puskesmas Hanura
Hanura, Indonesia · Not yet recruiting
Dr Moses Laman and Dr Brioni Moore
Alexishafen, Papua New Guinea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.